Skip to content

Natural History of Autoimmune Diabetes and Its Complications

Natural History of Autoimmune Diabetes and Its Complications

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00896610
Enrollment
356
Registered
2009-05-11
Start date
2009-05-13
Completion date
2020-09-30
Last updated
2020-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus Type 1, Diabetes Mellitus Type 2

Keywords

Diabetes Type II, Diabetes Type 1, Autoimmunity, Type 1 Diabetes, Type 2 Diabetes, Autoimmune Diabetes, At Risk Diabetes

Brief summary

Background: * Diabetes is a disease defined by abnormally high blood sugar (glucose) levels. Glucose is an essential source of energy for the body s cells, but insulin is required to move the glucose into the cells. Insulin is a hormone produced by the pancreas that allows glucose to enter cells. * In diabetes, the body is unable to supply enough insulin to meet its demands. The problem may be a low supply of insulin or a high demand for insulin. Someone who has been diagnosed with diabetes has lost much of their insulin-producing capacity. Clinical studies have shown that good control of blood sugar is essential to prevent diabetes complications like damage to the eyes, kidneys, nerves, and blood vessels. Objectives: * To establish a relationship with several individuals with diabetes caused by the immune system attacking the body s insulin-producing cells in order to: * Explore why the immune system attacks insulin-producing cells. * Understand why some individuals develop diabetes-related complications and others do not. * Develop therapies to improve how patients can control their blood sugar levels. * Continue to follow subjects who have completed or are considering other NIH diabetes-related studies. * To develop improved tests for determining an individual s risk for developing diabetes and/or to accurately diagnose the exact type of diabetes. Eligibility: * Individuals who have been diagnosed with or are at risk for developing diabetes. Design: * Standard physical examination and clinical tests to determine if the patient has diabetes or to confirm a particular type of diabetes: * None of the treatment in this study is experimental. * Patients will receive a separate consent form for any special tests needed to learn more about their particular type of diabetes. * Patients may be asked to provide additional urine and blood samples for use in laboratory research about diabetes. * Researchers may offer medical treatment advice for diabetes, or explain how to improve patients diabetes management skills.

Detailed description

Individuals with known or suspected autoimmune mediated diabetes, or healthy individuals at risk for developing the disease, will be evaluated at the NIH Clinical Center. Studies will include characterizing the disease s clinical and laboratory features, observing the natural history of the disease and its complications, evaluating responses to standard treatments. Protocol enrollees may be asked to contribute blood and/or urine samples for immunological research studies, and/or for studies designed to find parameters that increase a subject s risk for diabetes and/or its associated complications.

Interventions

None listed

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Lead SponsorNIH

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

-INCLUSION CRITERIA: i. Clinical diagnosis of diabetes, either type 1 (T1D) or insulin-requiring type 2 (T2D), ii. Healthy individuals who may be at risk for developing diabetes, iii. Individuals with suspected immune mediated diabetes, iv. Willingness of the patient or guardian to give informed consent and assent.

Exclusion criteria

i. Concomitant medical problems which would confound the interpretation studies of the autoimmune beta cell destructive process ii. Concomitant medical, surgical, or other conditions for which adequate facilities or funds are not available to support their care at the NIH. iii. Any other co-existing condition/circumstances that would make a subject unsuitable to participate in the study, as deemed by the investigators.

Design outcomes

Primary

MeasureTime frameDescription
Blood glucose levelevery 3 monthsBlood glucose level within a range appropriate for the patient's condition.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026